CurrentUnitedHealthcarePolicy CS036IN.13

Electrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Indiana Only)

State-specific UnitedHealthcare medical policy for Indiana governing coverage and medical necessity criteria for transcutaneous, functional, neuromuscular, and other electrical stimulation modalities for pain treatment and muscle rehabilitation. Affects providers treating Indiana members and submitting claims for these services.

Policy Summary

PayerUnitedHealthcare

PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Indiana Only)

Policy CodePolicy CS036IN.13

Change TypeNo material change

Effective DateMay 1, 2026

Next Review DateN/A

Key ActionFor TENS, providers must refer to InterQual CP: Durable Medical Equipment, Transcutaneous Electrical Nerve Stimulation (TENS) for the specific medical necessity clinical coverage criteria.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Indiana-onlystate applicability

2026-05-01effective date

InterQualTENS clinical criteria source

80%high responder rate (example)

Insufficient

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

restorative neurostimulation

Coverage Criteria and Evidence Summaries

Functional Electrical Stimulation (FES) - Covered Indications

FES is proven and medically necessary as a component of a comprehensive ambulation rehabilitation program in individuals with lower limb paralysis due to spinal cord injury (SCI) when ALL of the following are met:

FES - required conditions: Demonstration of intact lower motor units (L1 and below) (both muscle and peripheral nerves)

FES - required conditions: Muscle and joint stability for weight bearing at upper and lower extremities with balance and control to maintain an upright support posture independently

FES - required conditions: Demonstration of brisk muscle contraction

FES - required conditions: Demonstration of sensory perception sufficient for muscle contraction

FES - required conditions: High level of motivation, commitment, and cognitive ability for device use

FES - required conditions: Ability to transfer independently

FES - required conditions: Demonstration of independent standing tolerance for at least 3 minutesat least 3 minutes

FES - required conditions: Demonstration of hand and finger function to manipulate controls

FES - required conditions: Post-recovery from SCI and restorative surgery of at least 6 monthsat least 6 months

FES - required conditions: Absence of hip and knee degenerative disease

FES - required conditions: Absence of history of long bone fracture secondary to osteoporosis

FES - coverage limitation: FES is unproven and not medically necessary for any indication other than lower limb paralysis due to SCI meeting the criteria above

Neuromuscular Electrical Stimulation (NMES) - Covered Indications

NMES is proven and medically necessary for treating any of the following indications:

NMES covered indications: Disuse muscle atrophy when BOTH of the following are met: (1) the nerve supply to the muscle is intact; and (2) the disuse atrophy is non-neurological in origin (e.g., casting, splinting, contracture)

NMES covered indications: When used as part of a comprehensive lower limb rehabilitation program following total knee arthroplasty

NMES covered indications: To improve upper extremity function in persons with partial paralysis following stroke when used as part of a comprehensive rehabilitation program

NMES coverage limitation: NMES is unproven and not medically necessary for conditions not meeting the criteria above

TENS - Covered When InterQual Criteria Met

Transcutaneous electrical nerve stimulation (TENS) coverage stance

TENS - InterQual reference: TENS is proven and medically necessary in certain circumstances; refer to InterQual CP: Durable Medical Equipment, Transcutaneous Electrical Nerve Stimulation (TENS) for the specific medical necessity clinical coverage criteria.

Unproven / Not Medically Necessary Procedures

The following modalities are unproven and not medically necessary due to insufficient evidence of efficacy:

Unproven modalities: Interferential therapy (IFT) for musculoskeletal disorders or to facilitate soft tissue or bone fracture healing

Unproven modalities: Microcurrent electrical nerve stimulation (MENS)

Unproven modalities: Percutaneous electrical nerve stimulation (PENS) / percutaneous neuromodulation therapy (PNT)

Unproven modalities: Percutaneous electrical nerve field stimulation (PENFS)

Unproven modalities:

FES and neuromuscular electrical stimulation evidence statements

Evidence summaries and conclusions for FES and related neuromuscular electrical stimulation modalities

FES evidence - general: Evidence shows potential benefits (improved muscle strength, aerobic capacity, respiratory function, gait parameters, and QOL) particularly when FES is combined with exercise, but effectiveness varies by condition, injury severity, and timing; studies are limited by small sizes, inconsistent protocols, and short follow-up.

Hayes HTA conclusions for SCI: Hayes HTA found low-quality evidence (rating C) overall: in adults with complete motor SCI most studies report improved muscle strength and ambulation outcomes though study quality was low; in incomplete motor SCI RCTs showed improved muscle strength but inconsistent effects on endurance, walking ability, bone density, and QOL.

Long-term cohort findings: Cohort and nonrandomized studies (e.g., FES cycling) report substantial gains in muscle mass, strength, reduced intramuscular fat, and improved neurologic scores and QOL, but these are limited by nonrandomized design and small samples.

HTA Evidence Summary

Summary of evidence-based stance from Health Technology Assessments

HTA summary: Hayes HTAs and other HTAs conclude the overall evidence for FES and some NMES applications is low to very low quality, with inconsistent benefits versus comparators (e.g., AFOs) and a need for additional standardized RCTs to determine long-term functional and QOL effects.

Spinal Cord Injury

SCI evidence highlights

SCI cohort and RCT findings: Controlled and cohort studies in SCI report improved motor-sensory scores, increased muscle mass, reduced intramuscular fat, greater muscle strength, reduced spasticity, and improved QOL with long-term FES cycling; however, evidence includes small cohorts and variable designs limiting generalizability.

Cerebral Palsy

Cerebral palsy evidence

CP evidence summary: Systematic reviews and meta-analyses report that FES can increase walking speed, step length, ankle dorsiflexion angle, strength, selective motor control, balance, and gait kinematics in children with CP, but evidence for activity/participation improvements is limited and studies are heterogeneous and often small; adverse events are generally minor (skin irritation, acceptance issues).

Cerebrovascular Accident (Stroke)

Stroke (CVA) evidence

Acute/subacute stroke: Some RCTs and reviews indicate FES-assisted cycling or FES plus rehabilitation can improve trunk control, walking distance, and select functional outcomes in early/subacute stroke, but overall evidence quality is low to moderate and heterogeneous.

Subacute/chronic stroke: Larger multicenter RCTs have shown no significant improvement in primary walking outcomes in some populations (e.g., Matsumoto et al.), while smaller studies reported gait parameter benefits versus AFO; HTAs conclude inconsistent evidence for durable functional/QOL improvements.

Coverage by clinical indication

Summary coverage stance by indication based on evidence in this section

Poststroke upper extremity: FES added to conventional occupational/physical therapy is at least as effective as conventional therapy alone for some outcomes (low-quality evidence); more RCTs needed for long-term efficacy and parameter optimization.

Poststroke foot drop: FES may improve ankle dorsiflexion, balance, and functional mobility and when combined with supervised exercise can improve gait speed vs supervised exercise alone; evidence is mixed and heterogenous.

CCFES: Contralaterally controlled FES showed greater improvement than cyclic NMES in some upper extremity measures in small studies, but data are limited and heterogeneous.

MS foot drop: Low-quality evidence suggests FES improves walking speed/duration and perceived exertion similarly to AFOs; minor adverse events reported.

Poststroke motor rehabilitation

Evidence summary for NMES/CCFES in poststroke rehabilitation

Poststroke motor rehabilitation evidence: RCTs and systematic reviews show mixed results: some trials report improvements in manual dexterity or specific measures (Box and Block, ARAT, FMA-UE) with CCFES or NMES, while meta-analyses demonstrate inconsistent superiority; study limitations include small samples, short durations, and heterogeneity.

Poststroke dysphagia

Evidence summary for NMES for poststroke dysphagia

Poststroke dysphagia evidence: Systematic reviews of RCTs indicate NMES combined with conventional swallowing therapy may improve swallowing outcomes, but heterogeneity and variable quality limit firm conclusions; NICE recommends use only under special arrangements for governance/research.

COPD / respiratory indications

Evidence summary for NMES in COPD and respiratory conditions

COPD/respiratory evidence: Multiple RCTs and meta-analyses report NMES plus pulmonary rehabilitation can improve 6-minute walk distance, quadriceps strength, some QOL measures, and may reduce mechanical ventilation time; evidence quality is variable and NMES is generally adjunctive to conventional rehab rather than a replacement.

Chronic low back pain

Evidence summary for IFT/TENS/EMS in low back pain

Chronic low back pain: Systematic reviews and meta-analyses show no consistent benefit of TENS over controls; IFT demonstrated superiority in a small number of trials with short-term pain/disability improvements but high heterogeneity and risk of bias; overall effects are often short-term and evidence limited.

Knee osteoarthritis

Evidence summary for IFT in knee osteoarthritis

Knee osteoarthritis: Network and meta-analyses indicate IFT may yield modest short- and long-term pain and short-term function improvements in knee OA trials, but effect sizes are inconsistent versus comparators (exercise, brace) and heterogeneity limits strong conclusions.

Evidence-based coverage considerations

Evidence summary relevant to coverage decisions

IFT and MENS evidence considerations: Some reviews report short-term pain and function benefits for IFT and MENS in select trials, but heterogeneity, small samples, and inconsistent comparators mean routine, unrestricted coverage is not broadly supported; consider case-by-case use with documentation of prior conservative care and objective outcomes.

Postoperative/fracture rehab: RCTs have not consistently demonstrated additional benefit of IFT when added to structured rehabilitation in postoperative or fracture settings, so routine adjunctive coverage is not supported without compelling evidence.

Evidence summary and guideline-aligned coverage stance

Evidence- and guideline-based stance for microcurrent therapies and PENS

Microcurrent (MCT/MENS): Small RCTs and systematic reviews show potential short-term pain improvements for select conditions but data are limited and long-term benefit is unproven; overall evidence insufficient for broad coverage.

PENS/PENFS: RCTs and meta-analyses show immediate to short-term pain improvements in some MSK conditions but heterogeneity and limited long-term data exist; NICE recommends against routine use for LBP and AAOS notes PENS requires trained practitioners — evidence supports cautious use and further research.

Coverage criteria considerations

Evidence-based considerations and implied criteria from cited studies and guideline statements

Pediatric PENFS candidate considerations: PENFS studies in children enrolled patients who had failed multiple pharmacologic therapies (registry: many had failed ≥4 therapies); evidence supports conditional use in difficult-to-treat pediatric DGBIs per ESPGHAN/NASPGHAN.

PNS candidate considerations: Percutaneous PNS (temporary or permanent) has RCT and observational support for selected chronic neuropathic pain refractory to conventional medical management, but evidence is device-specific and of variable quality; careful patient selection and documentation are required.

Candidate selection and trial criteria

Coverage contingent on evidence and guideline-based selection:

Implantable PNS candidacy: Implantable PNS is supported for patients with moderate to severe chronic pain refractory to two or more conservative treatments (ASIPP level III/fair); documentation of failed conservative therapies is expected.two or more failed conservative treatments

Trial-to-implant approach: Temporary percutaneous PNS trials (commonly ~60 days) with demonstration of clinically meaningful response (e.g., ≥50% pain reduction) are commonly used to select candidates for permanent implantation.≥50% pain reduction during trial

Evidence summary for efficacy

Efficacy and durability findings (informational for coverage decisions):

Reported responder rates: Published RCTs and case series report variable responder rates (e.g., 60% in some PNS trials; 67% ≥50% pain relief at 12 months in SPRINT; 87% responder rate at 12 months in Nalu IPG RCT), with associated functional gains and opioid reductions in many studies.

Evidence limitations: Heterogeneity in populations, small samples, short durations, and potential conflicts of interest limit generalizability and strength of efficacy conclusions.

Coverage conclusions and conditions

Coverage stance based on available evidence in this document segment:

PNFS/SubQ add-on (FBSS): Subcutaneous (PNFS/SubQ) add-on to SCS may be reasonable for FBSS patients with persistent back pain after successful SCS trial for leg pain, supported by RCT data showing higher ≥50% back pain reduction at 3 months with SubQ add-on.

PNFS standalone: Small RCT evidence suggests PNFS may be effective for localized chronic back pain but data are limited; coverage may be conditional or investigational depending on payer policy.

PEMF: Evidence for PEMF is mixed with some short-term benefits in OA and LBP trials but heterogeneity and small studies limit conclusions; routine coverage for pain indications is not supported without stronger evidence.

PEMF for fracture healing: Current evidence does not consistently demonstrate benefit for enhancing fracture healing; routine use is not supported.

Restorative neurostimulation — trial-aligned criteria

Evidence and trial eligibility commonly required in studies of restorative neurostimulation:

Restorative neurostimulation trial-aligned criteria: Patient has refractory mechanical chronic low back pain with impaired multifidus control, has failed conservative management (e.g., >90 days medical management plus at least one attempt of PT), and meets severity measures similar to pivotal trials (eg ODI 30-60; NRS 6-9); not a candidate for, or has failed, other surgical/interventional options as applicable.>90 days

Scrambler therapy — evidence summary

Scrambler therapy observations and study populations:

Scrambler therapy evidence: Evidence comprises small RCTs, single-arm pilots, and meta-analyses showing marginal to short-term pain reduction across heterogeneous conditions (CIPN, poststroke pain, PDN); long-term sustained effects are inconsistent and quality of evidence is low to very low.

Evidence-informed coverage considerations

Coverage stance informed by evidence summaries and clinical guidelines

Scrambler therapy synthesis: Systematic reviews and RCTs report short-term analgesic benefit and favorable safety but are limited by small sizes, heterogeneity, and potential bias; guideline bodies (ASCO, ESMO/EONS/EANO) advise against routine use for CIPN outside trials.

Translingual stimulation synthesis: PoNS/TLS trials combined with PT show gait and balance improvements in mmTBI and MS in small RCTs, but evidence is inconclusive and requires larger sham-controlled trials for definitive support.

FES coverage is narrowly focused: FES is medically necessary only as part of a comprehensive ambulation rehabilitation program for lower limb paralysis due to spinal cord injury (SCI) when all listed trial-aligned criteria are met (intact lower motor units L1 and below; muscle/joint stability for independent upright support; brisk muscle contraction and adequate sensory perception; ability to transfer and independently stand for at least 3 minutes; hand/finger function to operate controls; high motivation and cognitive ability; ≥6 months post recovery from SCI/restorative surgery; and absence of hip/knee degenerative disease or osteoporotic long-bone fracture history).

Uses of FES outside these specified SCI ambulation rehabilitation criteria are considered unproven and not medically necessary based on the policy's statement that FES for other indications lacks sufficient evidence of efficacy.

Across multiple indications the evidence is limited and inconsistent: studies are frequently small, heterogeneous in protocols, of short duration, and at risk of bias, yielding mixed findings about functional and long-term benefits. These evidence-quality limitations underpin statements in the policy that several applications remain investigational or unsupported.

Because of this mixed evidence base, the policy treats modalities with uncertain or inconsistent trial results conservatively — either restricting coverage to specific, trial-like populations (e.g., the FES SCI criteria) or designating other modalities as unproven/not medically necessary until larger, higher-quality RCTs establish clinically meaningful, durable benefit.

Clinical trials commonly applied exclusion criteria that are relevant to coverage decisions: examples include severe cognitive or communication impairment, major cardiopulmonary/renal/hepatic disease, presence of cardiac pacemakers, psychiatric disorders, foot drop due to peripheral nerve injury (distinct from central causes), and inability to complete continuous therapy or follow-up. Payers may consider these study-based exclusions when adjudicating medical necessity.

Some protocols also required objective diagnostic confirmation (for example, stroke documented by CT/MRI and defined disease duration) and functional thresholds for enrollment; absence of such supporting documentation in the medical record may increase the risk of denial.

Several devices and indications have only very small, single‑center, unblinded RCTs or limited pre‑post reports (for example, device-specific reports such as the MyndMove assessments). Such limited single‑center evidence is at high risk of bias and is insufficient to establish generalizable efficacy; these limitations justify excluding or deferring routine coverage until larger multicenter RCTs are available.

The policy explicitly notes that procedures or devices supported primarily by these small, high‑risk studies require further investigation before being considered established therapy.

Certain NMES applications remain investigational: the policy notes that further investigation is needed before clinical usefulness can be considered proven, reflecting mixed trial results, small sample sizes, and heterogeneous protocols across NMES studies.

This uncertainty applies across some rehabilitative and adjunctive NMES uses where benefits for endurance, durable functional recovery, or clinically important secondary outcomes were not consistently demonstrated.

Interferential therapy (IFT) evidence is judged insufficient: the policy states there is inadequate high‑quality data to support IFT for musculoskeletal pain, bone fractures, or nonsurgical soft tissue healing because most studies are small, heterogeneous, and short‑term.

Given these limitations, IFT is listed among modalities that are unproven and not medically necessary for those indications.

The policy references NICE guidance that IFT should not be offered for knee osteoarthritis, chronic primary pain, or low back pain owing to insufficient and inconsistent evidence; NICE also recommends against offering IFT for low back pain with or without sciatica.

These guideline conclusions reinforce the policy’s stance that routine coverage of IFT for OA and LBP is not supported without stronger evidence or compelling case‑by‑case justification.

Microcurrent electrical nerve stimulation (MENS/MCT) has been studied in small RCTs and case series but lacks large, well‑controlled trials; the policy states that available peer‑reviewed evidence is insufficient to draw conclusions about safety or efficacy for decreasing pain or facilitating healing.

Because of limited sample sizes and heterogeneity, the clinical utility of MENS/MCT remains uncertain and the modality is considered investigational in this policy.

NICE guidance cited in the policy recommends against percutaneous electrical nerve stimulation (PENS) for low back pain with or without sciatica because the available trials were small and low quality, with no sustained benefit beyond 4 months.

Accordingly, the policy treats PENS as an unproven option for LBP and flags the intervention for restricted use or exclusion where guideline‑based decisions are applied.

Multiple interventions are specifically identified as lacking sufficient high‑quality evidence (for example, certain PENFS/IB‑Stim applications and device‑specific uses); the policy indicates these should be considered investigational or not medically necessary until stronger, consistent evidence emerges.

Health technology assessments and systematic reviews informing the policy generally call for larger, blinded, multicenter RCTs to resolve current uncertainty before routine coverage is recommended.

The policy notes absence of peer‑reviewed published evidence for some commercial systems or for particular indications (for example, the Nalu system per Hayes 2023), and that lack of published data may justify excluding those systems or indications from coverage pending supportive evidence.

When device‑specific published data are lacking, evidence assessments recommend awaiting rigorous clinical studies before granting routine coverage.

Pulsed electromagnetic field (PEMF) therapy is not supported for routine use to enhance acute fracture healing: a systematic review found no consistent, statistically significant effects on radiographic union across available RCTs.

Restorative neurostimulation for chronic low back pain is judged to have insufficient published evidence to support efficacy; the policy cites ECRI/Hayes assessments calling for additional larger comparative studies before coverage can be broadly endorsed.

Evidence assessments from ECRI and Hayes raise common caveats about restorative neurostimulation: available trials are small, often single‑center or with high risk of bias, sometimes industry‑funded, and have limited blinding and short follow‑up, all of which reduce confidence in the reported outcomes.

Because of these methodological concerns, the policy treats restorative neurostimulation as investigational or not sufficiently proven for routine coverage until more robust independent data are available.

Major oncology and guideline bodies (ASCO; ESMO/EONS/EANO) do not recommend scrambler therapy for chemotherapy‑induced peripheral neuropathy (CIPN) outside clinical trials because randomized trials are few, small, and yield inconsistent effectiveness results.

The policy cites these guideline positions to justify restricting scrambler therapy to research settings or considering it not medically necessary for CIPN when used outside trials.

Device regulatory status does not equate to broad coverage: several product codes exist for electrical stimulation technologies, but many peripheral nerve field stimulation devices used in studies are off‑label uses of spinal cord stimulation hardware and lack specific FDA approvals for pain or muscle rehabilitation.

The policy emphasizes that FDA product codes or device listings may be informational but are not, by themselves, sufficient justification for coverage absent supporting clinical evidence.

The reference list included in the policy provides supporting literature and technology‑assessment citations but does not itself specify additional coverage exclusions; references are provided to document the evidence base used to inform the policy statements.

Applicable Procedure, HCPCS, and Device Codes

Applicable CPT/HCPCS (group 1)mixed

0278T	Transcutaneous electrical modulation pain reprocessing (e.g., scrambler therapy), each treatment session (includes placement of electrodes).
0783T	Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use of equipment.
63650	Percutaneous implantation of neurostimulator electrode array, epidural.
63655	Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural.

Applicable CPT/HCPCS (group 2)mixed

63663	Revision including replacement, when performed, of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed.
63664	Revision including replacement, when performed, of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed.
63685	Insertion or replacement of spinal neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64555	Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve).
64567	Percutaneous electrical nerve field stimulation, cranial nerves, without implantation.
64596	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array.
64597	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; each additional electrode array.
64598	Revision or removal of neurostimulator electrode array, peripheral nerve, with integrated neurostimulator.
64999	Unlisted procedure, nervous system.

Additional HCPCS/L-codesmixed

E1399	Durable medical equipment, miscellaneous.
L8678	Electrical stimulator supplies (external) for use with implantable neurostimulator, per month.
L8679	Implantable neurostimulator, pulse generator, any type.
L8680	Implantable neurostimulator electrode, each.
L8682	Implantable neurostimulator radiofrequency receiver.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.
L8686	Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension.
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension.
L8688	Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension.
S8130	Interferential current stimulator, 2 channel.

1–10 of 11

1/2

FES devices verified by CMS PDAC for E0770mixed

(PDAC listing)

Devices verified to be reported with HCPCS code E0770 include Deluxe Digital Electronic Muscle Stimulator (Drive Medical); NESS L300 and H200 (Bioness); Odstock ODFS Pace FES System (Odstock Medical/Boston Brace); WalkAide (Innovative Neurotronics).

inv-69: Independent standing tolerance — key value

Independent standing toleranceDemonstration of independent standing tolerance for at least 3 minutes

Other standing-related criteriaMuscle and joint stability for weight bearing with ability to maintain an upright support posture independently

Transfer abilityAbility to transfer independently

Prior Authorization, Documentation, and Billing Guidance

Prior Authorization

Prior Authorization / Managed Codes Note

Codes marked with an asterisk (*) in the Applicable Codes list are not managed for medical necessity review for Indiana at the policy effective date. Refer to UnitedHealthcare Community Plan of Indiana prior authorization and notification lists for current managed codes.

E1399: Durable medical equipment, miscellaneous
L8678-L8688: Implantable neurostimulator supplies and components
S8130-S8131: Interferential current stimulators (not managed for IN)

Note

Hayes HTA Informs Authorization

Hayes health technology assessments and evolving evidence reviews cited throughout this policy may be used to inform prior authorization decisions. When Hayes rates evidence as low or evolving, use that assessment to guide documentation requests, but evaluate each request against payer-specific PA criteria.

Hayes FES assessments (SCI, stroke, foot drop, upper extremity)

Required Prior Conservative Treatments and Sequencing

TENS/InterQual reference and NMES rehab program requirement

TENS and NMES policy references: For TENS, refer to InterQual CP: Durable Medical Equipment, Transcutaneous Electrical Nerve Stimulation for authoritative coverage criteria; NMES coverage requires condition-specific documentation that nerve supply is intact or that NMES is used as part of a defined rehabilitation program.

Conservative treatment commentary

Conservative sequencing expectation: Evidence heterogeneity and limited high-quality RCTs support a conservative-first approach (trial of standard therapy/physical therapy) prior to advanced neurostimulation in many indications.

FES evidence often adjunct vs conventional therapy

Treatment Frequency, Duration, and Trial Lengths

inv-187: Functional Electrical Stimulation — frequency/duration commentary

Typical use contextFES studied as a component of comprehensive ambulation or exercise training programs, often adjunctive to conventional rehabilitation

Training course examplesClinical trials have used structured training courses (e.g., 6-week FES programs in CHF and other populations)

Evidence limitationsProtocols, stimulation parameters, and long-term frequency/duration vary across studies and are not standardized

inv-188: FES training — 6-week training programs studied; capture common regimen lengths

Common regimen length6-week training programs have been studied (example: 6-week FES program in CHF RCT)

Follow-up horizon

Imaging and Physiologic Testing Requirements

Billing Rule

CPT code descriptions reference fluoroscopy when performed

Certain CPT codes for spinal neurostimulator implantation/revision explicitly include 'including fluoroscopy, when performed' in the code descriptions; imaging (fluoroscopy) is commonly used during these procedures and should be documented when performed.

Document imaging modality used (fluoroscopy) and imaging guidance details in operative report

Billing Rule

Imaging guidance commonly used for PNS lead placement (document if used)

The PNS coding and device sections describe implanted or percutaneous systems; imaging requirements for PNS placement are not universally specified in these chunks, though imaging guidance is often used in practice.

If imaging guidance used for lead placement, document modality and findings

Procedures and Indications Considered Not Medically Necessary

Not covered modalities (policy lists): Interferential therapy (IFT); Microcurrent electrical nerve stimulation (MENS/MCT); Percutaneous electrical nerve stimulation (PENS/PNT); Percutaneous electrical nerve field stimulation (PENFS); Percutaneous peripheral nerve stimulation (PNS) for indications not supported by evidence; Peripheral subcutaneous field stimulation (PSFS/PNFS); Pulsed electromagnetic field stimulation (PEMF/PES); Restorative neurostimulation; Scrambler therapy; Translingual stimulation for gait rehabilitation.

The policy designates these modalities as unproven or not medically necessary because the peer‑reviewed evidence is insufficient in quality, quantity, or durability to establish safe and effective use for the listed indications.

Interventions listed as not medically necessary include device‑based PNS applications and other percutaneous/stimulation modalities when evidence is weak or inconsistent; the policy highlights that many PNS studies are small, heterogeneous, and of limited quality, supporting a noncoverage stance for unsupported indications.

Where guideline or HTA reports indicate minimal or unclear support, the policy treats the related interventions as not medically necessary pending higher‑quality evidence.

PEMF and restorative neurostimulation are explicitly addressed in the policy’s not‑covered or investigational lists given systematic review findings showing no consistent fracture‑healing benefit for PEMF and HTA/assessment conclusions of insufficient evidence for restorative neurostimulation in CLBP.

These statements reflect synthesis of systematic reviews and clinical evidence assessments cited in the policy.

IFT is included among modalities considered not medically necessary for knee osteoarthritis and low back pain when guideline bodies (such as NICE) recommend against its use due to lack of demonstrated clinical benefit in randomized trials.

Background and Scope

Background: Electrical stimulation modalities deliver alternating or pulsed electrical waveforms via surface electrodes, percutaneous needles, or implanted leads to elicit muscle contraction, modulate peripheral or central pain signaling, or support rehabilitative function.

Modalities discussed in this policy include TENS, FES, NMES, PENS, PENFS, PNS, IFT, MENS/MCT, PEMF, restorative neurostimulation, scrambler therapy, and translingual stimulation, each with differing mechanisms, delivery methods, and evidence bases referenced throughout the policy.

Definitions of Terms and Modalities

inv-133: Electrical stimulator — definition entry

DefinitionDevice that provides direct, alternating, pulsating and/or pulsed waveform energy to exercise muscles, demonstrate muscular response, relieve pain or incontinence, or provide test measurements

Electrode typesElectrodes may be indwelling, implanted transcutaneous, or surface

Adjustable parametersDevices may include controls for pulse length, pulse repetition frequency, pulse amplitude, and triggering modes

inv-134: Functional electrical stimulation (FES) — definition entry

DefinitionApplication of electric current to intact nerve fibers to cause purposeful contraction enabling or enhancing functions such as standing, ambulation, grasping, respiration, or bowel/bladder voiding

Modes and goals

Policy Summary

PayerUnitedHealthcare

PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Indiana Only)

Policy CodePolicy CS036IN.13

Change TypeNo material change

Effective DateMay 1, 2026

Next Review DateN/A

Key ActionFor TENS, providers must refer to InterQual CP: Durable Medical Equipment, Transcutaneous Electrical Nerve Stimulation (TENS) for the specific medical necessity clinical coverage criteria.

SourceLink

On This Page

Percutaneous peripheral nerve stimulation (PNS) for indications not otherwise supported*

Unproven modalities: Peripheral subcutaneous field stimulation (PSFS) / peripheral nerve field stimulation (PNFS)

Unproven modalities: Pulsed electromagnetic field stimulation (PEMF / PES)

Unproven modalities: Restorative neurostimulation

Unproven modalities: Scrambler therapy

Unproven modalities: Translingual stimulation for gait rehabilitation

Footnote: *For information regarding percutaneous peripheral nerve stimulation for occipital neuralgia and headache, refer to the Occipital Nerve policy

Evidence limitations: Common limitations across FES/NMES literature include heterogeneity of devices and protocols, small sample sizes, lack of blinding, and limited long-term durability data, requiring further high-quality RCTs to define optimal parameters and populations.

CHF/cardiopulmonary indications: FES can improve peak VO2, 6MWT distance, and QOL compared with control in CHF trials, but traditional exercise often produces greater gains.

NMES for orthopedic rehabilitation: NMES plus conventional rehab can reduce pain and improve quadriceps strength and some functional outcomes after joint replacement and ACL surgery, although trials are heterogeneous and small.

Restorative neurostimulation for CLBP: Evidence is insufficient to support restorative neurostimulation for CLBP as standard therapy; further large comparative studies are needed.

inv-70: Post-recovery from SCI and restorative surgery — key value

Post-recovery durationPost-recovery from SCI and restorative surgery of at least 6 months

Motivation and cognitive requirementsDemonstration of a high level of motivation, commitment, and cognitive ability for device use

Hand function requirementDemonstration of hand and finger function to manipulate controls

Hayes PNS/SPRINT and ReActiv8 reviews

Prior Authorization

Prior Authorization: Evidence-Based Eligibility

Prior authorization decisions should mirror clinical trial eligibility used in high-quality studies when applicable. Requests for device-based therapies should document that the patient meets inclusion criteria analogous to RCTs or large cohort studies that informed evidence reviews.

Document stroke timing (acute, subacute, chronic) and imaging confirmation
Specify muscle strength grades (e.g., manual muscle test scores used in trials)
Show prior treatment failures and duration consistent with trial enrollment (e.g., ≥90 days conservative care for ReActiv8)

Prior Authorization

FES with Conventional Therapy (PA Guidance)

For functional electrical stimulation (FES) used for poststroke rehabilitation or foot drop, prior authorization reviewers should expect concurrent conventional therapy (PT/OT) to be documented, as most positive trial results evaluated FES as an adjunct to supervised rehabilitation.

Document frequency and duration of concurrent PT/OT sessions
Note whether FES was delivered as assistive (AFO comparison) or rehabilitative adjunct
If no concurrent supervised therapy is documented, include rationale and evidence for isolated FES use

Note

Prior Authorization Not Addressed in This Excerpt

This excerpt does not provide an explicit universal rule on prior authorization for all modalities; some modalities reference external criteria (e.g., InterQual for TENS) or state that coverage decisions depend on evidence quality and program governance.

Refer to InterQual CP criteria for TENS coverage
No single PA policy in this excerpt governs all neuromodulation or electrotherapy services

Prior Authorization

Special Arrangements / Program Enrollment

NICE recommends that transcutaneous NMES for oropharyngeal dysphagia should only be used with special arrangements for clinical governance, consent, audit, or research. For such indications, prior authorization may require evidence of program enrollment, IRB oversight, or documented research governance.

If NMES for dysphagia is proposed, document study/registry enrollment or governance arrangements
Include patient consent and audit plan when applicable

Prior Authorization

Prior Authorization Likely for PENS / PENFS / PENS-Related Therapies

Given limited and heterogeneous evidence and provider training needs, prior authorization is recommended for PENS, PENFS, and related therapies to verify indication, prior conservative care, and device/operator qualifications.

Document provider training/certification for PENS where required
List prior conservative therapies attempted and durations
Specify device make/model and parameters used

Prior Authorization

Prior Authorization Recommended for PENFS / PNS

For PENFS and PNS in pediatric or adult populations, prior authorization is recommended to document indication, prior therapies, and that enrollment followed guideline or society recommendations when applicable.

PENFS in pediatric DGBIs: document prior pharmacologic therapy failures (e.g., ≥4) as in registry studies
PNS requests: include prior CMM details and objective pain measures

Prior Authorization

Prior Authorization Expectation

Where randomized controlled trials and technology assessments support device therapies (e.g., some PNS trials, ReActiv8 RESTORE trial), prior authorization is generally expected so reviewers can confirm trial-like eligibility, prior conservative therapy failure, and device specifics.

Confirm trial responder thresholds used in studies (e.g., ≥50% pain reduction) when applicable
Document prior conservative management attempts and durations (e.g., >90 days)

Prior Authorization

Prior Authorization Recommended for ReActiv8

For the ReActiv8 restorative neurostimulation system, prior authorization is recommended to document refractory mechanical CLBP with multifidus dysfunction, failure of conservative therapies (including PT and medications), and imaging or physiologic evidence as specified in FDA labeling and trial inclusion criteria.

Document ODI and NRS scores consistent with trial eligibility (e.g., ODI 30–60; NRS 6–9)
Show >90 days of prior medical management and at least one attempt of PT
Provide imaging/physiologic evidence of multifidus dysfunction when available

Note

Device-Specific FDA Indications (Informational)

FDA approvals and device-specific indications are informational and do not by themselves guarantee coverage. Use FDA product codes and PMA/PMA supplement pages to verify labeled indications when assessing requests.

ReActiv8 PMA (product code QLK) — review labeling for indicated population
Search FDA device database by product code (e.g., GZI for FES) to confirm device-specific claims

Denial Risk

Documentation Insufficiency

Medical record documentation must fully support medical necessity. Insufficient, illegible, or missing documentation may result in denial of prior authorization or claim payment.

Include relevant history, exam findings, and diagnostic test results
Maintain legible records and make them available upon request

Denial Risk

Evidence Quality Risk

Evidence quality limitations noted in Hayes, ECRI, NICE, and other reviews (small sample sizes, heterogeneity, risk of bias, short follow-up) increase the risk of coverage denial or requirement for additional documentation to justify off-guideline uses.

Low/very low GRADE or Hayes rating (e.g., C or evolving) should prompt stricter PA scrutiny
Heterogeneous device protocols and short-term outcomes may require supplemental justification

Denial Risk

Study-Based Exclusion Criteria (May Inform Coverage Denials)

Study-based exclusion criteria cited in trials can inform coverage denials when present in the patient (e.g., pacemaker, severe cardiopulmonary disease, inability to evoke contraction, cognitive impairment). Reviewers may use trial exclusions as operational contraindications.

Pacemaker or implanted electronic device may exclude certain stimulation therapies
Severe cognitive/communication impairment or inability to comply with therapy sessions
Peripheral nerve injury as cause of deficit when trial excluded such etiologies

Denial Risk

Evidence Limitations Risk

When evidence is limited, inconsistent, or of low quality (as noted for PEMF, restorative neurostimulation in some reviews, and several neuromodulation modalities), expect requests to carry a higher denial risk unless strong supporting documentation is provided.

PEMF for OA/knee pain: limited and heterogeneous evidence — may be denied without strong documentation
Restorative neurostimulation: conflicting assessments (RESTORE positive; ECRI/Hayes note limitations) — document trial eligibility and prior conservative care

Denial Risk

NICE Guidance May Prompt Denials

NICE recommendations (e.g., NMES for dysphagia, IFT/PENS guidance) that advise against routine use or recommend research-only use may be cited as rationale for denying coverage for routine clinical use outside trial or governance arrangements.

NMES for dysphagia: NICE recommends use only with special arrangements — may prompt denial for routine care
IFT/PENS: NICE recommendations against routine use for LBP may inform noncoverage decisions

Denial Risk

Provider Training / Access May Affect Feasibility

Limited access to trained providers (e.g., PENS requires trained practitioners per AAOS) or lack of provider credentialing may affect feasibility and be used as a basis to require additional documentation or to deny requests when safe delivery cannot be assured.

If local provider lacks documented PENS training/certification, require referral to qualified practitioner
Document operator experience for ultrasound-guided PENS or implantable device placement

Denial Risk

Evidence Insufficiency May Trigger Denial

Insufficient or low-quality evidence for certain modalities (e.g., PENFS/PNS in some populations, PEMF) may trigger coverage denial absent robust, condition-specific documentation and justification.

PENFS/PNS: small heterogeneous studies — require strong prior conservative care documentation
PEMF: single small trials and mixed systematic review results — expect denials for routine use

Denial Risk

PEMF Insufficient Evidence — Denial Risk

PEMF therapies have mixed and generally low-quality evidence for many pain indications; denials are likely unless trial-like eligibility, objective impairment, and failure of conservative therapy are documented.

Document trial duration and prior PT/exercise attempts before PEMF
Provide objective outcome measures and rationale for PEMF over alternatives

Denial Risk

Guideline-Based Denial Risk

Guideline recommendations (e.g., ASCO, ESMO, NICE) that advise against routine use of modalities such as scrambler therapy for certain indications may support noncoverage or requirement for trial enrollment prior to approval.

Scrambler therapy for CIPN: ASCO recommends only in trials/outside routine use
PENS/IFT for LBP: NICE recommends against routine use — may inform denials

Note

No Denial Triggers Are Stated in These References

The referenced materials include guidance, HTAs, systematic reviews, and device assessments but do not, in themselves, create specific denial triggers; PA decisions should document rationale when a modality is covered despite limited evidence.

References are informational — cite specific evidence elements used to approve or deny requests
No automatic coverage/denial solely based on a literature citation

Documentation Required

Example Trial Inclusion / Exclusion

Trials cited in the literature defined explicit inclusion and exclusion examples. When requesting authorization, providers should mirror these where appropriate (e.g., stroke confirmation by CT/MRI; muscle strength grade thresholds; duration since index event).

Stroke: imaging confirmation and disease duration (e.g., 1–12 months for some trials)
SCI: recent injury <6 months and specified strength grades (grade 1–2)
Knee OA trials: exclude prior knee surgery or recent intra-articular injections

Documentation Required

Required Clinical Documentation Elements

Required clinical documentation elements include: history and physical exam findings that match trial populations, diagnostic imaging or physiologic testing (when required by device labeling), baseline pain and function scores, and records of prior conservative therapies and durations.

Baseline outcome scores (e.g., NRS, ODI, WOMAC) and objective functional measures
Documentation of prior conservative care: PT dates, medication trials, injections, timelines

Documentation Required

Suggested Supporting Clinical Documentation

Suggested supporting clinical documentation includes objective measures, prior multimodal pain management attempts, trial-phase outcomes (for staged PNS/PENS), and reasons for progression to implantable or advanced therapies.

Trial stimulation results and responder thresholds (e.g., ≥50% pain reduction)
Records of prior multimodal pain management including medication dosing and PT participation
Rationale for advancing to implantable therapy (failure of ≥2 conservative modalities)

Documentation Required

Suggested Documentation Elements from Studies

Studies commonly collected detailed documentation elements that can be requested for PA: timing since index event, paresis severity, standardized outcome measures, stimulation parameters, and adherence to therapy protocols.

Stroke timing and Brunnstrom or Modified Ashworth scores where relevant
Device parameters: frequency, pulse width, session duration and total sessions
Adherence logs for home-based NMES/NMES-assisted rehab programs

Documentation Required

Trial Responder Documentation

Document trial responder thresholds and how they were measured in studies (for example, a responder defined as ≥50% pain reduction or specified ODI improvement). Use these thresholds when evaluating trial-phase success prior to implant.

PNS/PERC trial definitions: ≥50% pain reduction commonly used
ReActiv8 trial composite response: ≥15-point ODI and/or ≥50% pain reduction

Documentation Required